In the media

Video, newspaper article and podcast overview:

Latest news can be followed on this link:

https://www.linkedin.com/in/fredrik-schjesvold-8373522

Videos (chronologically, newest on top):

Date Information:
20.08.2023 Healthtalk:
Slik blir dine immunceller «oppgradert» til banebrytende medisin
19.01.2023 Healthtalk:
Toppmøte ASH: – Jeg ble kjempeskeptisk da jeg så det djerve studiedesignet
2023 Levemedmyelomatose:
De mest stilte spørsmålene om myelomatose
15.12.2022 Dagens medisin:
DM Arena Post-ASH 2022
Siste nytt fra ASH innen myelomatose
15.12.2022 Healthtalk:
– Dette var høydepunktene på American Society of Hematology
13.12.2022 Healthtalk:
Vi har fått et nytt angrepsmål mot myelomatose: Bispesifikt antistoff og CAR-T lykkes i studier
11.12.2022 Healthtalk:
Dette er de viktigste terapiformene på hematologikonferanse i USA
19.10.2022 Healthtalk:
Lang ventetid på nye legemidler - men nå tror Legemiddelverket på bedring
18.10.2022 Healthtalk:
Nå får legene en sterkere rolle i Nye metoder
21.08.2022 Healthtalk:
Kliniske studier kan spare helsevesenet for millionbeløp
2021 Healthtalk:
Fredrik Schjesvold forlarer hvorfor CAR T virker bedre en tradisjonell immunterapi
2021 Healthtalk:
Fredrik Schjesvold forklarer BiTE teknologien og Celgene sin BiTE
2021 Janssen Medial Cloud:
Nyresvikt som komplikasjon ved myelomatose av Fredrik Schjesvold
2021 Janssen Medial Cloud:
Anemi som komplikasjon ved myelomatose av Fredrik Schjesvold
05.02.2021 Fra Blodkreftforeningen:
Webinar om myelomatose, i samarbeid med International Myeloma Foundation.
December 2020 OncologyTube.com:
ASH2020: Multiple myeloma cancer research: 1411 isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma. ICARIA-MM subgroup analysis.
10.12.2020 Dagens Medisin:
DM Arena Digital Post American Society of Hematology (ASH) / hematologi
16:20-16:30: Siste nytt innen myelomatose, Fredrik Schjesvold
08.12.2020 Dagens Medisin
– Det siste store er bispesifikke antistoffer
08.12.2020 HealthTalk:
Banebrytende CAR-T studie med T-celler fra friske donorer
08.12.2020 HealthTalk:
Denne teknologien kan revolusjonere kreftbehandlingen
05.12.2020 HealthTalk:
Myelomatose: Venetoclax + cobimetinib gir større respons enn venetoclax alene.
24.09.2020 Dagens Medisin:
DM Arena Digital Post ESMO
19.09.2020 Dagens Medisin:
Se debatten: – Hva er rettferdige priser på kreftmedisiner?
02.08.2020 NRK:
Kreftpasienter får ikke tilgang til ny lovende medisin
August 2020 Phillips Gilmore Oncology Communications:
RRMM: How to Optimize Treatment Sequence
22-23.06.2020 From Health Talk:
Ny behandlingsmulighet for pasienter med AL amyloidose (YouTube clip)
En ny standardbehandling for myelomatose?
21.06.2020 Fredrik Schjesvold interviewed about myeloma treatment on NRK Kveldsnytt (major national evening news programme , Norwegian Broadcasting Corporation):
Link to the Kveldsnytt clip - Kreftbehandling
25.05.2020 5 SPØRSMÅL OM MYELOMATOSE (BENMARGSKREFT) v/ Overlege Fredrik Schjesvold, Oslo Myelomatosesenter
YouTube link - Link to video via Amgen home page
Dec 2019 Dr Fredrik Schjesvold speaks to ecancer at the 2019 American Society of Hematology (ASH) meeting in Orlando (7-10 Dec 2019):
KRd consolidation in MM patients with a positive PET-CT after standard first-line therapy: Results from the phase II CONPET trial
15.11.19 The Norwegian "Blodkreftforeningen" (Leukemia Association) had a seminar on Myelomatosis in Oct/Nov 2019. Here is Fredrik Schjesvold's talk, in Norwegian (link to YouTube video):
Myelomatose. Fredrik Schjesvold. Oslo myelomatosesenter; tilgang til ny behandling gjennom studier
18.06.19 Video from MEDtalks from EHA 2019:
EHA 2019: Ixazomib did not have an adverse impact on quality of life in newly diagnosed multiple myeloma
Speaker: Fredrik Schjesvold
From bestprac.no - published 18.06.19 - registering (free) required to get access.
15.06.19 Video - Dr Evangelos Terpos, Prof Michele Cavo, Dr Eloísa Riva and Dr Fredrik Schjesvold discuss the deepening response seen with the use of ixazomib as a maintenance therapy following autologous stem cell transplantation
Use of maintenance therapy following ASCT and real world treatment patterns in multiple myeloma
From ecancertv.org - published 15.06.19 - registering (free) required to get access.
May 2018 The 4th World Congress on CONTROVERSIES IN MULTIPLE MYELOMA (COMy) May 3-5, 2018 Paris, France
  Video presentation of Oslo Myeloma Center

Podcasts:

27.05.2022 Healthtalk:
Ep. 5: CAR-T - Dine egne T-celler blir omgjort til en behandling (healthtalk.no)
10.02.2021 From Radium, a podcast produced by RADFORSK:
Episode 162: Handlingsplan for kliniske studier
March 2021 From Kreftpodden:
Ep. 18: CAR-T og innovasjon - Fredrik Schjesvold
February 2020 From Radium, a podcast produced by RADFORSK:
Episode 115: Fredrik Schjesvold om kliniske studier - spesielt CAR-T
August 2019 From Radium, a podcast produced by RADFORSK:
Episode 87: Helsenæring, dette skal vi bli best på. Live fra Arendalsuka
09.04.18 From the NRK radio programme "Ekko": 
"Møt en forsker: Fredrik Schjesvold"
29.05.18 From the NRK radio programme "Ekko": 
"Kan benmargskreft kureres?"

From newspapers and web sites:

22.06.2023 Best Practice Nordic:
EHA23 Insights into the Changing Landscape of Myeloma Treatments
22.05.2023 Onkologisk tidsskrift:
Overlege: CAR T for myelomatose er den beste behandlingen vi noen gang har sett
24.04.2023 Healthtalk:
Ny studie viser stor effekt av celleterapi: – Håp om at noen kreftpasienter kan bli kurert
08.02.2023 Oslo University Hospital, Ekspertsykehuset:
Immunterapi revolusjonerer behandlingen av myelomatose - benmargskreft
07.02.2023 HealthTree Foundation for Multiple Myeloma:
Expanding Clinical Trials: Norway’s Gift to Myeloma?
22.12.2022 Medwatch:
Targovax har fått tommel opp for studie på benmargskreft - inkluderer første pasient tidlig i 2023
15.12.2022 Sykepleien:
Ny behandlingsmetode for beinmargskreft lover godt
24.11.2022 Healthtalk:
GSK stopper salget av blodkreftmedisin i USA – salget fortsetter i Europa
29.08.2022 Dagens Medisin:
Ny medisin innføres mot benmargskreft
26.08.2022 Dagens Medisin:
Nedslående trend for kliniske studier
22.07.2022 Dagens Medisin:
Innspill fra fageksperter – en viktig del av Nye metoder
20.07.2022 Dagens Medisin:
Beslutningsforum legger feilaktige premisser til grunn for avgjørelsene
28.06.2022 Healthtalk:
Norsk kreftvaksine godkjent til bruk i kliniske studier i USA
12.05.2022 Healthtalk:
Skal teste norsk kreftvaksine mot RAS-mutert benmargskreft
12.04.2022 Healthtalk:
Revlimid går av patent - og tas i bruk: – Flere år for sent, mener Kreftforeningen
21.02.2022 Dagens Medisin:
Venter en bølge av nye dyre behandlinger
14.02.2022 Healthtalk:
To kombinasjonsbehandlinger mot benmargskreft fikk ja - to fikk nei. - Det er jo som forventet
31.01.2022 Dagens Medisin:
Ut mot Legemiddelverkets vurdering av legemiddel mot kreft
27.01.2022 Dagens Medisin:
Legemiddelverket spiller med åpne kort
18.01.2022 Dagens Medisin:
Økning av pasienter inkludert i myelomatose-studier til tross for pandemi
02.03.2021 Dagens Medisin:
Har tatt inn 500 kreftpasienter i studier – kritisk til «motstand mot industrien»
02.03.2021 Dagens Medisin:
Hvordan få flest mulig pasienter med i kliniske industristudier?
16.02.2021 Dagbladet:
Kreftsyke Terje (76) må betale selv
2021 Aleris kreftsenter:
- En tilfeldig blodprøve avslørte beinmargskreft i emning
10.12.2020 HealthTalk:
Slik fant norske forskere en ny bildediagnostisk metode som kan oppdage benmargskreft tidligere
07.12.2020 Dagens Medisin:
Benmargskreft: Skal inkludere 400 pasienter i ny studie
04.12.2020 Dagens Medisin:
Studie viser effekt av ny behandling mot benmargskreft
24.11.2020 HealthTalk:
To nye genterapier til behandling av blodkreft kan bli tatt i bruk i Norge
22.10.2020 Dagens Medisin:
Første norske pasient får CAR-T-behandling mot benmargskreft
10.10.2020 From nrk.no:
Derfor får mange hull i skjelettet ved beinmargskreft
12.08.2020 Aftenposten:
Jo, helsevesenet nekter kreftpasienter gratis medisin | Et samlet kreftmiljø i Norge
14.07.2020 From Aftenposten, chronicle:
Hvorfor nektes kreftpasienter gratis medisin?
01.07.2020 From Dagsavisen, debate letter:
Tida overmoden for lovendring (PDF document)
21.06.2020 From Dagens Medisin:
Slår alarm om tilgang til medisiner for pasienter med benmargskreft
June 2020 From the health web site "Alt om din helse", interview with Fredrik Schjesvold:
Benmargskreft – kreftsykdommen der legene har mest å spille på
05.12.2019 From Aftenposten, kronikk:
Nytt lovforslag kan være til skade for norske pasienter | Fredrik Schjesvold og syv medforfattere fra det norske kreftmiljøet
07.06.2019 From Dagens Medisin, 07.06.2019:
Åpnet studie-poliklinikk for pasienter med benmargskreft
05.06.2019 From forskning.no, 05.06.2019:
Nytt legemiddel mot beinmargskreft med lovende resultater
26.04.2019 From Aftenposten, 26.04.2019:
Sigurd Herrlin Sørensen deltar i en kreftstudie. Det sparer Rikshospitalet for minst én million i medisinutgifter.
21.11.2018 From Dagens Medisin, 21.11.2018:
Kreftleger mener «uvillige» sjefer står i veien for kliniske studier
20.11.2018 From Dagens Medisin, 20.11.2018:
135 millioner til forskning på behandling
Nov 2018 From Alt om din helse, november 2018:
Myelomatosebehandlingen blir stadig bedre
21.04.2018 From VG, 21.02.2018:
Kreftsyk general tester ny behandling: – Jeg hadde begynt å se litt mørkt på det hele
20.04.2018 From Inven2, 20.04.2018:
Bringer banebrytende behandling for benmargskreft til Norge
01.02.2018 From Dagens medisin, 01.02.2018:
Har inkludert 100 pasienter i studier
21.08.2017 From VG, 21.08.2017:
Nytt medikament mot benmargskreft godkjent i Norge – etter nesten to år i kø
20.06.2017 From Aftenposten, 20.06.2017:
Kreftpasient måtte google seg frem til norsk studie som kan gi ham ekstra levetid

 

Myeloma research funded by national clinical research program KLINBEFORSK

Fredrik Schjesvold (photo: Dagens Medisin)
Fredrik Schjesvold (photo: Dagens Medisin)

Fredrik Schjesvold, head of the Oslo Myeloma Center at Oslo University Hospital, receives 20 mill NOK from The national programme for clinical therapy research - KLINBEFORSK.
The supported project is entitled "The REMNANT study – Does early treatment of relapse increase survival in myeloma?" 
This is one of four projects coordinated from OUH receiving funding from KLINBEFORSK in 2018. The other three are headed by Michael Bretthauer, Guro Elisabeth Lind and Øyvind Molberg.

The 4th World Congress on CONTROVERSIES IN MULTIPLE MYELOMA (COMy) May 3-5, 2018 Paris, France

Allogeneic stem cell transplantation for high-risk cytogenetics frontline

Video presentation of Oslo Myeloma Center:

This film shows the breadth of features at Oslo Myeloma Center including:

  1. A large clinical research activity. (2017: 84 enrolled patients in 11 clinical studies, from phase 1 to phase 3; academic and industry studies). Biggest center in the Nordics, and biggest center in the Nordic Myeloma Study Group. Weekly group meetings, and twice weekly tumor boards. 5-days-a-week study outpatient clinic.
  2. Our first phase-1-study is now ongoing, and we’re the biggest center. Jan 22nd a patient of ours received the triplet treatment, as the first patient in the world. He might be interviewed.
  3. Strong collaboration with the translational group KG Jebsen for B cell malignancies (Newly founded), pathophysiology, immunotherapy and drug sensitivity center.
  4. Large transplant center: 124 autologous transplants in 2017.
  5. In our hospital we have high-tech facilities for cytogenetics, flowcytometrics, pathology, and PET-CT.
  6. We have the largest cell laboratory in public health care in Europe, and have CAR-T-cell-experience from two previous studies. We have an amyloidosis group with regular tumor boards, and who have developed a lasermicrodissection-mass spectrometry program.

 

Schjesvold interviewed for national broadcasting corporation (NRK) radio programme "Ekko"

Fredrik Schjesvold, leader of the "Oslo Myeloma Center" research group at the Department of Haematology at Oslo University Hospital, has  been interviewed twice by the national broadcasting corporation NRK for the the popular radio programme "Ekko", under the headlines "Meet a researcher" and "Can myeloma be cured?" . Schjesvold has also been interviewed for an international multiple myeloma podcast. Furthermore, a video presenting the Oslo Myeloma Center has been produced.

Links:

From the NRK radio programme "Ekko":
Broadcasted April 2018:
"Møt en forsker: Fredrik Schjesvold".

Broadcasted May 2018:
"Kan benmargskreft kureres?"

Multiple myeloma podcast: interview with Fredrik Schjesvold (in English, 25 minutes)

 

Multiple myeloma podcast: interview with Fredrik Schjesvold (in English, 25 minutes) (click on link to open mp3 file)

Click here to listen directly:

This podcast is exploring the scientific myeloma landscape in the Nordics. In this episode, Dr. Fredrik Schjesvold talks about the current and future perspectives for clinical studies and treatments – and the infrastructure he is part of establishing with Oslo Myeloma Center.

This podcast is part of a series of podcasts within hematology developed and sponsored by Janssen Nordics. www.janssen.com/norway.